3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move

When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals (NASDAQ: MDGL). Earlier this year, the up-and-coming biotech received approval of a pioneering liver-disease treatment. And from how things looks right now, there isn't much reason to expect this budding player's growth to taper off anytime soon.In fact, the bull thesis for buying it is still looking quite good. Here are three reasons why it's a canny move to buy the stock.When it was approved in March 2024, Rezdiffra became the only medicine approved by the Food and Drug Administration (FDA) to treat metabolic-associated steatohepatitis (MASH), a disease that's characterized by fatty deposits on the liver, toughening and stiffening of liver tissue (fibrosis), and eventually scarring of the liver (cirrhosis).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool